Overview

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to assess the efficacy of a weekly treatment regimen of STA-4783 and paclitaxel in comparison to paclitaxel alone on tumor response in metastatic melanoma patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Synta Pharmaceuticals Corp.
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel